Press Release: European Medicines Agency completes review of protamine-containing medicines

Author (Corporate)
Series Title
Series Details EMA/CHMP/717405/2012 (16.11.12)
Publication Date 16/11/2012
Content Type

The European Medicines Agency (EMA), in November 2012, finalised a review into the supply chain for protamine-containing medicinal products and concluded that there would be no supply shortage for medicinal products containing protamine in the European Union (EU).

Protamine sulphate is used to counteract the anticoagulant action of heparin in the treatment of bleeding resulting from heparin overdose. It is also used to neutralise the effect of heparin, particularly in cardiac surgery.

Source Link Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/11/news_detail_001657.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/CHMP/717405/2012 (16.11.12) http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500134849.pdf

Subject Categories
Countries / Regions